Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAM R TAUB

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1346355161
CMS profile
657996
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$247,175.35

169 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAM R TAUB

NPI 1346355161 · CMS profile ID 657996

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346355161?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAM R TAUB, NPI 1346355161, CMS profile ID 657996. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346355161?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PAM R TAUB, NPI 1346355161, CMS profile ID 657996. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346355161?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PAM R TAUB, NPI 1346355161, CMS profile ID 657996, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1346355161?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

169 matching records · $247,175.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 169 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–169 of 169.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $48.9702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119276658 CMS
Medtronic, Inc. $12.2402/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119276660 CMS
Medtronic, Inc. $26.5002/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119276648 CMS
Edwards Lifesciences Corporation $2,187.5002/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138886689 CMS
Edwards Lifesciences Corporation $183.9702/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138886691 CMS
Eli Lilly and Company $303.0001/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135258541 CMS
Eli Lilly and Company $89.5901/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135304346 CMS
Eli Lilly and Company $46.9701/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135304738 CMS
Novartis Pharmaceuticals Corporation $125.8401/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087347164 CMS
Novartis Pharmaceuticals Corporation $119.1401/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087347166 CMS
Medtronic, Inc. $2,500.0001/25/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112075447 CMS
Lexicon Pharmaceuticals, Inc. $2,250.0001/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081702451 CMS
Novo Nordisk Inc $1,550.0001/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097322768 CMS
SANOFI-AVENTIS U.S. LLC $349.9701/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139748736 CMS
Novo Nordisk AS $54.7001/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096551967 CMS
Novo Nordisk AS $103.5801/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096552757 CMS
Novo Nordisk AS $593.5301/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096552925 CMS
Novo Nordisk AS $20,731.2501/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096552973 CMS
Novo Nordisk AS $6,639.3601/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096553177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $218,874.22 213
PY2020 $104,020.33 63
PY2021 $87,837.24 54
PY2022 $131,641.96 119
PY2023 $155,269.05 137
PY2024 $247,175.35 169
PY2025 $265,192.69 158

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $16,128.41 12
PY2025 Principal investigator $278,474.86 55
PY2024 Recipient $10,085.10 6
PY2024 Principal investigator $1,009,330.81 320
PY2023 Recipient $6,229.98 2
PY2023 Principal investigator $466,768.64 104
PY2022 Recipient $286.43 2
PY2022 Principal investigator $77,235.41 26
PY2021 Principal investigator $35,864.25 7
PY2020 Recipient $2,020.55 3
PY2020 Principal investigator $25,941.00 2
PY2019 Principal investigator $48,128.70 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,065.35 12/18/2025 Non-covered Recipient Entity
ONE NOTE VENTURES
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190314209
Recipient Cleerly, Inc. $1,500.00 11/20/2025 Covered Recipient Physician Cleerly Web Series No dispute reported 06/30/2026 1241145307
Principal investigator 1 Ionis Pharmaceuticals, Inc. $754.00 10/08/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IS354CS9 No dispute reported 06/30/2026 1246788485
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,100.00 10/08/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IS354CS9 No dispute reported 06/30/2026 1246788489
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,667.10 10/08/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IS354CS9 No dispute reported 06/30/2026 1246788494
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,900.00 10/08/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IS354CS9 No dispute reported 06/30/2026 1246788498
Recipient Boehringer Ingelheim International GmbH $66.59 09/06/2025 Covered Recipient Physician A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220623862
Recipient Boehringer Ingelheim International GmbH $424.17 09/06/2025 Covered Recipient Physician A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220623864
Recipient Boehringer Ingelheim International GmbH $32.36 09/05/2025 Covered Recipient Physician A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220623866
Recipient Boehringer Ingelheim International GmbH $8.46 09/05/2025 Covered Recipient Physician A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220623868
Recipient Boehringer Ingelheim International GmbH $76.99 09/04/2025 Covered Recipient Physician A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220623860
Recipient Novartis Pharma AG $15.40 08/28/2025 Covered Recipient Physician CKJX839D12302 No dispute reported 06/30/2026 1248109815
Principal investigator 1 CSL Behring $399.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672256
Principal investigator 1 CSL Behring $852.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672258
Principal investigator 1 CSL Behring $999.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672260
Principal investigator 1 CSL Behring $1,596.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672262
Principal investigator 1 CSL Behring $1,995.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672264
Principal investigator 1 CSL Behring $2,149.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672266
Principal investigator 1 CSL Behring $2,872.80 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672268
Principal investigator 1 CSL Behring $3,325.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672270
Principal investigator 1 CSL Behring $3,990.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672272
Principal investigator 1 CSL Behring $4,855.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672274
Principal investigator 1 CSL Behring $21,280.00 08/27/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672276
Principal investigator 1 Dexcom, Inc. $144.00 06/05/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers - The SHIFT Study No dispute reported 06/30/2026 1250961380
Principal investigator 1 Dexcom, Inc. $1,815.66 06/05/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers - The SHIFT Study No dispute reported 06/30/2026 1250961384
Recipient Boehringer Ingelheim International GmbH $1,277.67 06/01/2025 Covered Recipient Physician A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220623858
Recipient Novartis Pharma AG $1,221.70 05/13/2025 Covered Recipient Physician CKJX839D12304 No dispute reported 06/30/2026 1248109485
Principal investigator 1 Dexcom, Inc. $2,870.00 05/09/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
FEASIBILITY AND EFFICACY OF TIME-RESTRICTED EATING IN DIABETES MANAGEMENT No dispute reported 06/30/2026 1250961376
Principal investigator 1 ARGENX US, INC. $13.15 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143432
Principal investigator 1 ARGENX US, INC. $95.40 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143435
Principal investigator 1 ARGENX US, INC. $95.40 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143438
Principal investigator 1 ARGENX US, INC. $78.45 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143442
Principal investigator 1 ARGENX US, INC. $159.00 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143446
Principal investigator 1 ARGENX US, INC. $94.14 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143449
Principal investigator 1 ARGENX US, INC. $181.68 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143453
Principal investigator 1 ARGENX US, INC. $181.68 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143456
Principal investigator 1 ARGENX US, INC. $156.90 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143460
Principal investigator 1 ARGENX US, INC. $105.20 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143464
Principal investigator 1 ARGENX US, INC. $78.90 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143468
Principal investigator 1 ARGENX US, INC. $159.00 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143472
Principal investigator 1 ARGENX US, INC. $159.00 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143476
Principal investigator 1 ARGENX US, INC. $127.20 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143481
Principal investigator 1 ARGENX US, INC. $127.20 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143485
Principal investigator 1 ARGENX US, INC. $31.80 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143489
Principal investigator 1 ARGENX US, INC. $95.40 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143495
Principal investigator 1 ARGENX US, INC. $95.40 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143499
Principal investigator 1 ARGENX US, INC. $13.15 05/02/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237143503
Principal investigator 1 CSL Behring $7.60 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672108
Principal investigator 1 CSL Behring $95.39 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672110
Principal investigator 1 CSL Behring $348.86 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672112
Principal investigator 1 CSL Behring $295.57 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672114
Principal investigator 1 CSL Behring $754.47 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672116
Principal investigator 1 CSL Behring $1,700.00 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672118
Principal investigator 1 CSL Behring $110.00 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672120
Principal investigator 1 CSL Behring $165.00 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672122
Principal investigator 1 CSL Behring $550.00 04/30/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672124
Principal investigator 1 CSL Behring $16.75 04/28/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672178
Recipient Novartis Pharma AG $9,035.12 04/23/2025 Covered Recipient Physician CKJX839D12304 No dispute reported 06/30/2026 1248109483
Principal investigator 1 CSL Behring $1,865.33 04/21/2025 Non-covered Recipient Entity
Regents Of The University Of California San Diego
Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) No dispute reported 06/30/2026 1252672176
Principal investigator 1 Dexcom, Inc. $540.00 04/19/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers - The SHIFT Study No dispute reported 06/30/2026 1250961378
Principal investigator 1 Dexcom, Inc. $1,350.00 04/19/2025 Covered Recipient Teaching Hospital
Ucsd Medical Center
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers - The SHIFT Study No dispute reported 06/30/2026 1250961382
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,921.91 03/31/2025 Non-covered Recipient Entity
UC SAN DIEGO HEALTH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190306069
Recipient Novartis Pharma AG $60.51 03/28/2025 Covered Recipient Physician CKJX839D12302 No dispute reported 06/30/2026 1248109813
Principal investigator 1 Novartis Pharmaceuticals Corporation $136,623.20 03/11/2025 Non-covered Recipient Entity
UC SAN DIEGO HEALTH
Impact of Inclisiran on Patients with Multiple Comorbidities in which there are Drug/Drug Interactions Limiting LDL/C Lowering No dispute reported 06/30/2026 1190306067
Recipient Novartis Pharmaceuticals Corporation $2,409.44 02/05/2025 Covered Recipient Physician CKJX839D12304 No dispute reported 06/30/2026 1190291801
Principal investigator 1 ARGENX US, INC. $11,953.47 02/03/2025 Non-covered Recipient Entity
The Regents of the University of California
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1237158632
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,500.35 01/30/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190300391